Hisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%

Stock News04-07

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a year-on-year increase of 2.03%. Net profit attributable to shareholders of the listed company was 541 million yuan, a decrease of 10.06% compared to the previous year. Net profit after deducting non-recurring gains and losses was 586 million yuan, up 36.11% year-on-year. Basic earnings per share stood at 0.46 yuan. The company plans to distribute a cash dividend of 0.21 yuan per share (including tax) to all shareholders.

The 36.11% growth in net profit attributable to shareholders of the listed company after excluding non-recurring items was primarily driven by the company's continued efforts in promoting its formulated products, resulting in steady growth in product sales. Additionally, the ongoing optimization and upgrading of the marketing system led to improved operational management efficiency. Furthermore, by deepening refined production management and effectively implementing cost reduction and efficiency enhancement measures, the company's overall profitability continued to improve.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197239794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197239794","market":"fut","top_or_hot":-1,"title":"Hisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%","media":"Stock News","content":"<p>Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a year-on-year increase of 2.03%. Net profit attributable to shareholders of the listed company was 541 million yuan, a decrease of 10.06% compared to the previous year. Net profit after deducting non-recurring gains and losses was 586 million yuan, up 36.11% year-on-year. Basic earnings per share stood at 0.46 yuan. The company plans to distribute a cash dividend of 0.21 yuan per share (including tax) to all shareholders.</p>\n<p>The 36.11% growth in net profit attributable to shareholders of the listed company after excluding non-recurring items was primarily driven by the company's continued efforts in promoting its formulated products, resulting in steady growth in product sales. Additionally, the ongoing optimization and upgrading of the marketing system led to improved operational management efficiency. Furthermore, by deepening refined production management and effectively implementing cost reduction and efficiency enhancement measures, the company's overall profitability continued to improve.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHisun Pharma Reports 2025 Earnings with Net Profit Attributable to Shareholders of 541 Million Yuan, Down 10.06%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-07 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a year-on-year increase of 2.03%. Net profit attributable to shareholders of the listed company was 541 million yuan, a decrease of 10.06% compared to the previous year. Net profit after deducting non-recurring gains and losses was 586 million yuan, up 36.11% year-on-year. Basic earnings per share stood at 0.46 yuan. The company plans to distribute a cash dividend of 0.21 yuan per share (including tax) to all shareholders.</p>\n<p>The 36.11% growth in net profit attributable to shareholders of the listed company after excluding non-recurring items was primarily driven by the company's continued efforts in promoting its formulated products, resulting in steady growth in product sales. Additionally, the ongoing optimization and upgrading of the marketing system led to improved operational management efficiency. Furthermore, by deepening refined production management and effectively implementing cost reduction and efficiency enhancement measures, the company's overall profitability continued to improve.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1197239794","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197239794","pubTimestamp":1775564423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0188":"融资融券","BK0060":"抗癌","BK0239":"医药制造","BK0028":"国家队"},"translate_title":"海正药业公布2025年盈利归属股东净利润5.41亿元下降10.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) has released its annual report for 2025. During the reporting period, the company achieved revenue of 105.5 billion yuan, representing a year-on-year increase of 2.03%. Net profit attributable to shareholders of the listed company was 541 million yuan, a decrease of 10.06% compared to the previous year. Net profit after deducting non-recurring gains and losses was 586 million yuan, up 36.11% year-on-year. Basic earnings per share stood at 0.46 yuan. The company plans to distribute a cash dividend of 0.21 yuan per share (including tax) to all shareholders.\nThe 36.11% growth in net profit attributable to shareholders of the listed company after excluding non-recurring items was primarily driven by the company's continued efforts in promoting its formulated products, resulting in steady growth in product sales. Additionally, the ongoing optimization and upgrading of the marketing system led to improved operational management efficiency. Furthermore, by deepening refined production management and effectively implementing cost reduction and efficiency enhancement measures, the company's overall profitability continued to improve.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197239794","isCrawlerRequest":true}